Treatment Centers and Clinical Trials

You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.

Location

Treatments/Services

Treatment Centers

Richmond Road Diagnostic and Treatment Centre

Calgary, AB, Canada
Treatment Centers

OhioHealth Physician Group - Hematology/Oncology

Columbus, OH, United States
Treatment Centers

ROCHESTER SKIN LYMPHOMA MEDICAL GROUP, PLLC

Fairport, NY, United States
Treatment Centers

Rush University Medical Center

Chicago, IL, United States
Treatment Centers

The University of Kansas Hospital

Kansas City, KS, United States
Treatment Centers

The Warren Alpert Medical School of Brown University, Department of Dermatology

Providence, RI, United States
Treatment Centers

Fred Hutch Cancer Center

Seattle, WA, United States
Treatment Centers

Tulane University School of Medicine

New Orleans, LA, United States
Treatment Centers

University Dermatology Consultants, Inc.

Cincinnati, OH, United States
Treatment Centers

University Hospitals of Cleveland

Cleveland, OH, United States
Treatment Centers

University of Alabama Medical Center

Birmingham, AL, United States
Treatment Centers

University of California, San Francisco

San Francisco, CA, United States
Treatment Centers

University of Iowa Hospitals & Clinics

Iowa City, IA, United States
Treatment Centers

University of North Carolina Medical Center

Chapel Hill, NC, United States
Treatment Centers

University of Pittsburgh Medical Center

Pittsburgh, PA, United States
Treatment Centers

University of Rochester - Wilmot Cancer Institute

Rochester, NY, United States
Treatment Centers

University of Texas Southwestern Medical Center

Dallas, TX, United States
Treatment Centers

University of Virginia-Emily Couric Clinical Cancer Center

Charlottesville, VA, United States
Treatment Centers

University of Wisconsin - Madison

Madison, WI, United States
Treatment Centers

Vanderbilt University Medical Center

Nashville, TN, United States
Treatment Centers

Atrium Health Wake Forest Baptist

Winston-Salem, NC, United States
Treatment Centers

Winship Cancer Institute - Emory University

Atlanta, GA, United States
Treatment Centers

Mayo Clinic - Arizona Campus

Scottsdale, AZ, United States
Treatment Centers

Cleveland Clinic

Cleveland, OH, United States
Treatment Centers

Clinical Cancer Center, Froedtert Hospital

Milwaukee, WI, United States
Treatment Centers

Saint Louis University Cancer Center

St Louis, MO, United States
Treatment Centers

Washington University Medical Center - Siteman Cancer Center

St Louis, MO, United States
Treatment Centers

The Dermatology Clinic at University of Minnesota

Minneapolis, MN, United States
Treatment Centers

Henry Ford Hospital - Cutaneous Lymphoma Program

Detroit, MI, United States
Treatment Centers

University of Michigan Medical Center

Ann Arbor, MI, United States
Treatment Centers

Northwestern Medicine

Chicago, IL, United States
Treatment Centers

Yale University School of Medicine

New Haven, CT, United States
Treatment Centers

Penn Cutaneous Lymphoma Program

Philadelphia, PA, United States
Treatment Centers

Jefferson Cutaneous Lymphoma Clinic

Philadelphia, PA, United States
Treatment Centers

Boston Medical Center - Cutaneous Oncology Program

Boston, MA, United States
Treatment Centers

Center for Cutaneous Oncology at Dana-Farber/Brigham Cancer Institute

Boston, MA, United States
Treatment Centers

Beth Israel Deaconess Medical Center

Boston, MA, United States
Treatment Centers

Massachusetts General Hospital

Boston, MA, United States
Treatment Centers

INOVA Melanoma and Skin Oncology Center

Fairfax, VA, United States
Treatment Centers

Dartmouth Hitchcock Medical Center

Lebanon, NH, United States
Treatment Centers

Columbia University Irving Medical Center - Cutaneous Lymphoma Center

New York, NY, United States
Treatment Centers

NYU Grossman School of Medicine

New York, NY, United States
Treatment Centers

University of Texas MD Anderson Cancer Center

Houston, TX, United States
Treatment Centers

Moffitt Cancer Center

Tampa, FL, United States
Treatment Centers

Cleveland Clinic - Indian River Hospital

Vero Beach, FL, United States
Treatment Centers

Miami Cancer Institute BHSF

Miami, FL, United States
Treatment Centers

Levine Cancer Institute

Charlotte, NC, United States
Treatment Centers

Duke Cutaneous T-Cell Lymphoma Clinic and Research Center

Durham, NC, United States
Treatment Centers

UCHealth - University of Colorado Cancer Center - Anschutz

Aurora, CO, United States
Treatment Centers

Huntsman Cancer Institute

Salt Lake City, UT, United States
Treatment Centers

Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)

Stanford, CA, United States
Treatment Centers

Oregon Health & Science University (OHSU)

Portland, OR, United States
Treatment Centers

MUSC Cutaneous Lymphoma Clinic

Charleston, SC, United States
Treatment Centers

Johns Hopkins Dermatology

Baltimore, MD, United States
Treatment Centers

OU Physicians

Oklahoma City, OK, United States
Treatment Centers

City of Hope National Medical Center

Duarte, CA, United States
Treatment Centers

Chao Family Comprehensive Cancer Center

Orange, CA, United States
Treatment Centers

Mayo Clinic - Florida

Jacksonville, FL, United States
Treatment Centers

Fondazione IRCCS Ca' Granda

Milan, Italy
Treatment Centers

IU Simon Cancer Center

Indianapolis, IN, United States
Treatment Centers

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia
Treatment Centers

Westmead Hospital - University of Sydney

Westmead, NSW, Australia
Treatment Centers

Medical University of Graz

Graz, Austria
Treatment Centers

Medical University of Vienna

Vienna, Austria
Treatment Centers

Hôtel-Dieu - CHU de Nantes

Nantes, France
Treatment Centers

Helsinki University Hospital

Helsinki, Finland
Treatment Centers

Hospital Dresden-Friedrichstadt

Dresden, Germany
Treatment Centers

Charité University of Medicine Berlin

Berlin, Germany
Treatment Centers

HELIOS Klinikum Krefeld

Krefeld, Germany
Treatment Centers

Rabin Medical Center

Petah-Tikva, Israel
Treatment Centers

Rambam Medical Center

Haifa, Israel
Treatment Centers

Spedali Civili di Brescia

Brescia, Italy
Treatment Centers

Cutaneous Lymphoma Multidisciplinary Clinic - Lisbon

Lisbon, Portugal
Treatment Centers

Friedrich Schiller University

Jena, Thuringia, Germany
Treatment Centers

University Medical Centre - Mannheim

Mannheim, Baden-Württemberg, Germany
Treatment Centers

University of Essen

Essen, Germany
Treatment Centers

Semmelweis Medical School

Budapest, Hungary
Treatment Centers

Hospital Universitario 12 de Octubre

Madrid, Spain
Treatment Centers

Cutaneous Lymphoma Clinic - Kimberly and Eric J. Waldman Dept of Dermatology

New York, NY, United States
Treatment Centers

University Hospital Zurich - Department of Dermatology

Zurich, Switzerland
Treatment Centers

Memorial Sloan Kettering Cancer Center

New York, NY, United States
Treatment Centers

John Theurer Cancer Center at HUMC

Hackensack, NJ, United States
Treatment Centers

Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center

Morristown, NJ, United States
Treatment Centers

Johann Wolfgang Goethe-University Frankfurt

Frankfurt, Germany
Treatment Centers

OSU Comprehensive Cancer Center

Columbus, OH, United States
Treatment Centers

Roswell Park Comprehensive Cancer Center

Buffalo, NY, United States
Treatment Centers

St. Thomas Hospital - St Johns Department of Dermatology

London, United Kingdom
Treatment Centers

UAMS Cancer Center

Little Rock, AR, United States
Treatment Centers

Newnan Dermatology

Newnan, GA, United States
Clinical Trials

Phase 1 Trial of ST-001 nanoFenretinide

Description

Clinical Trials

Pembrolizumab - Stage IB-IV Mycosis Fungoides

Brief Summary:

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Clinical Trials

Dose-Escalation Trial Evaluating CPI-818

Brief Summary:

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Clinical Trials

Duvelisib + Nivolumab for the Treatment of MF and SS

Brief Summary:

Clinical Trials

Extracorporeal Photopheresis in Sezary Syndrome (ECP)

Brief Summary:

Clinical Trials

Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Brief Summary:

Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC

Brief Summary:

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Clinical Trials

Real World Observational Study of Poteligeo in Adult Patients With MF and SS

Brief Summary

This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Clinical Trials

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Ly

Brief Summary

Clinical Trials

Pembrolizumab in Combination With Gemcitabine in People With Advanced MF or SS

Brief Summary

The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT04960618#contacts-and-locations

Clinical Trials

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Brief Summary

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT03587844

Sponsors: Memorial Sloan Kettering Cancer Center

Clinical Trials

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Brief Summary

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

Website: https://clinicaltrials.gov/study/NCT05010005

Sponsor: Memorial Sloan Kettering Cancer Center

Eligibility Criteria

Permitted histologies include:

Clinical Trials

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Brief Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT05079282

Clinical Trials

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light (RW-HPN

Brief Summary

The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Clinical Trials

Ritlecitinib in CTCL

Brief Summary

The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.